reports
Lattice Biologics Ltd. Announces Management Cease Trading Order is Rev...
BELGRADE, Mont.--(BUSINESS WIRE)-- Lattice Biologics Ltd. (TSX-V: LBL) (OTCBB: LBLTF) (“Lattice Biologics” or the “Company”) announces the Company has successfully filed all necessary reporting documents and the preceding MCTO was revoked as of May 1, 2018. For the past few months, the Company provided default status reports in accordance with National Policy 12-203 – Management Cease Trade Orders. The Company’s audited annual financial statements, related management’s discussion and analysis and accompanying CEO and CFO ...
Lattice Biologics Ltd. Reports Fourth Quarter 2017, First Quarter 2018...
BELGRADE, Mont.--(BUSINESS WIRE)-- Lattice Biologics Ltd. (TSX-V: LBL) (OTCBB: LBLTF) (“Lattice Biologics” or the “Company”) announces financial results for the fourth quarter 2017, year ended September 30, 2017, and first quarter 2018: Highlights: Gross profit margin was 65.8% for the three months ended December 31, 2017, compared to 36.6% for the three months ended December 31, 2016. Cash flow positive from operations for the three months ended December 31, 2017. ...
Lattice Biologics Ltd. Announces Update to Management Cease Trade Orde...
BELGRADE, Mont.--(BUSINESS WIRE)-- Lattice Biologics Ltd. (TSX-V: LBL) (OTCQB: LBLTF) (“Lattice Biologics” or the “Company”) is providing this default status report in accordance with National Policy 12-203 – Management Cease Trade Orders. The Company’s audited annual financial statements, related management’s discussion and analysis and accompanying CEO and CFO certifications for the financial year ended September 30, 2017 (collectively, the “Required Filings”) would not be completed by the prescribed period for the filing of ...
Lattice Biologics Ltd. Announces Update to Management Cease Trade Orde...
BELGRADE, Mont.--(BUSINESS WIRE)-- Lattice Biologics Ltd. (TSX-V: LBL) (OTCQB: LBLTF) (“Lattice Biologics” or the “Company”) is providing this default status report in accordance with National Policy 12-203 – Management Cease Trade Orders. The Company’s audited annual financial statements, related management’s discussion and analysis and accompanying CEO and CFO certifications for the financial year ended September 30, 2017 (collectively, the “Required Filings”) would not be completed by the prescribed period for the filing of ...
Update March 28, 2018: Lattice Biologics Ltd. Management Cease Trade O...
BELGRADE, Mont.--(BUSINESS WIRE)-- Lattice Biologics Ltd. (TSX-V: LBL) (OTCQB: LBLTF) (“Lattice Biologics” or the “Company”) is providing this default status report in accordance with National Policy 12-203 – Management Cease Trade Orders. The Company’s audited annual financial statements, related management’s discussion and analysis and accompanying CEO and CFO certifications for the financial year ended September 30, 2017 (collectively, the “Required Filings”) would not be completed by the prescribed period for the filing of ...
Update March 14, 2018: Lattice Biologics Ltd. Management Cease Trade O...
BELGRADE, Mont.--(BUSINESS WIRE)-- Lattice Biologics Ltd. (TSX-V: LBL) (OTCQB: LBLTF) (“Lattice Biologics” or the “Company”) is providing this default status report in accordance with National Policy 12-203 – Management Cease Trade Orders. The Company’s audited annual financial statements, related management’s discussion and analysis and accompanying CEO and CFO certifications for the financial year ended September 30, 2017 (collectively, the “Required Filings”) would not be completed by the prescribed period for the filing of ...
Update February 28, 2018: Lattice Biologics Ltd. Cease Trade Order
BELGRADE, Mont.--(BUSINESS WIRE)-- Lattice Biologics Ltd. (TSX-V: LBL) (OTCQB: LBLTF) (“Lattice Biologics” or the “Company”) is providing this default status report in accordance with National Policy 12-203 – Management Cease Trade Orders. The Company’s audited annual financial statements, related management’s discussion and analysis and accompanying CEO and CFO certifications for the financial year ended September 30, 2017 (collectively, the “Required Filings”) would not be completed by the prescribed period for the filing of ...
Lattice Biologics Ltd. Announces Change in Director and Change in Stat...
BELGRADE, Mont.--(BUSINESS WIRE)-- Lattice Biologics Ltd. (TSX-V: LBL) (OTCQB: LBLTF) (“Lattice Biologics” or the “Company”) announces a change in its Board of Directors and chief operating officer. Board of Director Mario Stifano resigned his position effective December 12, 2017, due to conflicting time priorities. “We appreciate Mario’s time and dedication, and wish him the best in the future,” states Guy Cook, CEO. Darrell Holmes, chief operating officer, resigned his position on December 1, 2017, to...
Lattice Biologics Ltd. Reports Third Quarter 2017 Highlights
BELGRADE, Mont.--(BUSINESS WIRE)-- Lattice Biologics Ltd. (TSX-V: LBL) (OTCQB: LBLTF) (“Lattice Biologics” or the “Company”) announces financial results for the third quarter ended June 30, 2017: Highlights: Grenville Strategic Royalty debt restructuring significantly strengthens balance sheet Total liabilities decrease by $2.8 million for nine months ended June 30, 2017, a 27% reduction. AmnioBoost sales increased 61% quarter over quarter. ...
CORRECTING and REPLACING Notice of Lattice Biologics Ltd. Third Quarte...
BELGRADE, Mont.--(BUSINESS WIRE)-- The conference call dial-in number in the release dated August 25, 2017, should be: 863-208-0120 (instead of 213-416-1560). The corrected release reads: NOTICE OF LATTICE BIOLOGICS LTD. THIRD QUARTER 2017 FINANCIAL RESULTS CONFERENCE CALL Financial results to be released after market on Tuesday, August 29, 2017 Lattice Biologics Ltd. (TSX -V: LBL) (OTCQB: LBLTF) (the “Company”) announced today it will release its third quarter 2017 financial results a...
Ford Equity International Rating and Forecast Report
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.